(GALD) Galderma N - SW
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: SW (Switzerland) | Market Cap: 40.967m CHF | Total Return: 56.3% in 12m
Avg Turnover: 66.5M
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
P/E ratio 84.8
Tailwinds
No distinct edge detected
Galderma Group AG is a Switzerland-based healthcare company specializing in the global dermatology market. Its business model integrates three primary segments: injectable aesthetics, dermatological skincare, and therapeutic dermatology. The company manages a diverse portfolio of established brands, including Cetaphil, Restylane, and Dysport, targeting both consumer skincare needs and clinical medical conditions.
The specialty dermatology sector is characterized by high barriers to entry due to rigorous clinical trial requirements and intellectual property protections for proprietary formulations. Galderma competes in a market driven by aging populations and increasing consumer spending on aesthetic procedures. For a deeper look into the companys fundamentals, ValueRay provides comprehensive data tools.
Founded in 1981 and headquartered in Zug, Galderma operates as a large-cap entity within the specialty drug manufacturing industry. Its therapeutic reach extends from over-the-counter skincare solutions to prescription treatments for conditions such as acne, rosacea, and skin cancer.
- Injectable aesthetics demand drives volume growth in premium filler markets
- Cetaphil and Alastin expand market share in dermatological skincare
- Therapeutic pipeline approvals including Nemluvio accelerate specialty drug revenue
- Margin expansion follows operational deleveraging and high-margin product mix shift
| Net Income: 632.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 5.26 > 1.0 |
| NWC/Revenue: 7.04% < 20% (prev 11.56%; Δ -4.51% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.19b > Net Income 632.0m |
| Net Debt (2.45b) to EBITDA (1.11b): 2.21 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (236.8m) vs 12m ago -0.33% < -2% |
| Gross Margin: 67.07% > 18% (prev 69.15%; Δ -2.08% > 0.5%) |
| Asset Turnover: 41.71% > 50% (prev 21.60%; Δ 20.11% > 0%) |
| Interest Coverage Ratio: 4.84 > 6 (EBIT TTM 772.6m / Interest Expense TTM 159.8m) |
| A: 0.03 (Total Current Assets 2.44b - Total Current Liabilities 2.06b) / Total Assets 13.4b |
| B: 0.47 (Retained Earnings 6.35b / Total Assets 13.4b) |
| C: 0.06 (EBIT TTM 772.6m / Avg Total Assets 13.0b) |
| D: 1.55 (Book Value of Equity 8.15b / Total Liabilities 5.24b) |
| Altman-Z'' = 3.76 = AA |
| DSRI: 0.59 (Receivables 1.06b/910.0m, Revenue 5.42b/2.73b) |
| GMI: 1.03 (GM 69.15% / 67.07%) |
| AQI: 0.94 (AQ_t 0.76 / AQ_t-1 0.81) |
| SGI: 1.99 (Revenue 5.42b / 2.73b) |
| TATA: -0.04 (NI 632.0m - CFO 1.19b) / TA 13.4b) |
| Beneish M = -2.67 (Cap -4..+1) = A |
As of June 20, 2026, the stock is trading at CHF 172.40 with a total of 3,070,730 shares traded.
Over the past week, the price has changed by +2.40%,
over one month by +12.63%,
over three months by +19.29% and
over the past year by +56.26%.
Galderma N has no consensus analysts rating.
Market Cap USD = 51.3b (41.0b CHF * 1.2511 CHF.USD)
P/E Trailing = 84.7816
P/E Forward = 46.0829
P/S = 7.8167
P/B = 6.2609
P/EG = 1.9638
Revenue TTM = 5.42b USD
EBIT TTM = 772.6m USD
EBITDA TTM = 1.11b USD
Long Term Debt = 2.58b USD (from longTermDebt, last quarter)
Short Term Debt = 65.0m USD (from shortTermDebt, last quarter)
Debt = 2.90b USD (from shortLongTermDebtTotal, last quarter) + Leases 148.0m
Net Debt = 2.45b USD (calculated: Debt 2.90b - CCE 455.0m)
Enterprise Value = 53.7b USD (51.3b + Debt 2.90b - CCE 455.0m)
Interest Coverage Ratio = 4.84 (Ebit TTM 772.6m / Interest Expense TTM 159.8m)
EV/FCF = 49.86x (Enterprise Value 53.7b / FCF TTM 1.08b)
FCF Yield = 2.01% (FCF TTM 1.08b / Enterprise Value 53.7b)
FCF Margin = 19.86% (FCF TTM 1.08b / Revenue TTM 5.42b)
Net Margin = 11.65% (Net Income TTM 632.0m / Revenue TTM 5.42b)
Gross Margin = 67.07% ((Revenue TTM 5.42b - Cost of Revenue TTM 1.79b) / Revenue TTM)
Gross Margin QoQ = 65.13% (prev 69.12%)
Tobins Q-Ratio = 4.01 (Enterprise Value 53.7b / Total Assets 13.4b)
Interest Expense / Debt = 5.51% (Interest Expense 159.8m / Debt 2.90b)
Taxrate = 4.58% (30.3m / 661.3m)
NOPAT = 737.2m (EBIT 772.6m * (1 - 4.58%))
Current Ratio = 1.19 (Total Current Assets 2.44b / Total Current Liabilities 2.06b)
Debt / Equity = 0.36 (Debt 2.90b / totalStockholderEquity, last quarter 8.15b)
Debt / EBITDA = 2.21 (Net Debt 2.45b / EBITDA 1.11b)
Debt / FCF = 2.27 (Net Debt 2.45b / FCF TTM 1.08b)
Total Stockholder Equity = 7.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.86% (Net Income 632.0m / Total Assets 13.4b)
RoE = 8.07% (Net Income TTM 632.0m / Total Stockholder Equity 7.83b)
RoCE = 7.42% (EBIT 772.6m / Capital Employed (Equity 7.83b + L.T.Debt 2.58b))
RoIC = 6.62% (NOPAT 737.2m / Invested Capital 11.1b)
WACC = 8.95% (E(51.3b)/V(54.2b) * Re(9.16%) + D(2.90b)/V(54.2b) * Rd(5.51%) * (1-Tc(0.05)))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 36.76 | Cagr: -0.14%
[DCF] Terminal Value 76.05% ; FCFF base≈786.7m ; Y1≈901.8m ; Y5≈1.33b
[DCF] Fair Price = 66.58 (EV 18.1b - Net Debt 2.45b = Equity 15.6b / Shares 234.6m; r=8.95% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 98.46 | Revenue CAGR: 10.57% | SUE: -0.11 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.27 | Chg30d=-0.78% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=3.68 | Chg30d=-3.92% | Revisions=+33% | GrowthEPS=+42.9% | GrowthRev=+21.4%
EPS next Year (2027-12-31): EPS=6.41 | Chg30d=+0.75% | Revisions=+33% | GrowthEPS=+38.9% | GrowthRev=+18.0%
[Analyst] Revisions Ratio: +33%